MX355063B - Calcimiméticos y métodos para su uso. - Google Patents
Calcimiméticos y métodos para su uso.Info
- Publication number
- MX355063B MX355063B MX2014005662A MX2014005662A MX355063B MX 355063 B MX355063 B MX 355063B MX 2014005662 A MX2014005662 A MX 2014005662A MX 2014005662 A MX2014005662 A MX 2014005662A MX 355063 B MX355063 B MX 355063B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- calcimimetics
- effective
- levels
- kidney disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 2
- 239000000199 parathyroid hormone Substances 0.000 abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 abstract 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 abstract 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 abstract 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000002092 calcimimetic effect Effects 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000001631 haemodialysis Methods 0.000 abstract 1
- 230000000322 hemodialysis Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558389P | 2011-11-10 | 2011-11-10 | |
| PCT/US2012/064717 WO2013071262A1 (en) | 2011-11-10 | 2012-11-12 | Calcimimetics and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005662A MX2014005662A (es) | 2014-11-10 |
| MX355063B true MX355063B (es) | 2018-04-04 |
Family
ID=47258113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005662A MX355063B (es) | 2011-11-10 | 2012-11-12 | Calcimiméticos y métodos para su uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20140315809A1 (enExample) |
| EP (1) | EP2776129B2 (enExample) |
| JP (2) | JP6204369B2 (enExample) |
| CN (2) | CN109985228A (enExample) |
| AU (1) | AU2012335009B2 (enExample) |
| CA (1) | CA2854911C (enExample) |
| HK (1) | HK1202086A1 (enExample) |
| MX (1) | MX355063B (enExample) |
| WO (1) | WO2013071262A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3404102T1 (sl) | 2004-04-21 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti |
| SMT201700014T1 (it) | 2009-07-29 | 2017-03-08 | Kai Pharmaceuticals Inc | Agenti terapeutici per la riduzione dei livelli dell'ormone paratiroideo |
| SI3013318T1 (sl) * | 2013-06-28 | 2017-11-30 | Amgen Inc. | Stabilna tekoča oblika amg 416 (velkalcetid) |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| TW201615222A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 免疫疾病用藥臨床新應用 |
| RU2708068C2 (ru) | 2014-12-05 | 2019-12-04 | Алексион Фармасьютикалз, Инк. | Лечение судорог с использованием рекомбинантной щелочной фосфатазы |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| JP6868561B2 (ja) * | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| MX2018002121A (es) | 2015-08-17 | 2018-06-18 | Alexion Pharma Inc | Elaboracion de fosfatasas alcalinas. |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| CN109152820A (zh) | 2016-04-01 | 2019-01-04 | 阿雷克森制药公司 | 用碱性磷酸酶治疗肌肉无力 |
| EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
| US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| US11224637B2 (en) | 2017-03-31 | 2022-01-18 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
| WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
| EP3833377B1 (en) | 2018-08-10 | 2023-11-22 | Alexion Pharmaceuticals, Inc. | Bone healing at implants using alkaline phosphatase |
| EP3867650A1 (en) * | 2018-10-18 | 2021-08-25 | Fresenius Medical Care Holdings, Inc. | Techniques for modeling parathyroid gland functionality and calcimimetic drug activity |
| US12433938B2 (en) | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| TW202122410A (zh) * | 2019-12-09 | 2021-06-16 | 大陸商北京拓界生物醫藥科技有限公司 | 鈣敏感受體激動劑化合物及其應用 |
| EP4212542A4 (en) * | 2020-09-10 | 2024-08-28 | Shaanxi Micot Technology Co., Ltd. | BISPECIFIC FUSION POLYPEPTIDE COMPOUND |
| US12083169B2 (en) | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CN117295510A (zh) * | 2021-06-08 | 2023-12-26 | 北京拓界生物医药科技有限公司 | 一种钙敏感受体激动剂的组合物及其应用 |
| CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| AU3819497A (en) * | 1996-07-31 | 1998-02-20 | General Hospital Corporation, The | Novel parathyroid hormone-related peptide analogs |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| EP1301479A2 (en) | 2000-07-18 | 2003-04-16 | Bone Care International, Inc. | STABILIZED 1$g(a)-HYDROXY VITAMIN D |
| WO2003013543A1 (en) * | 2001-08-08 | 2003-02-20 | Genomed, Llc | Treatment or prevention of acute renal failure |
| US20060276534A1 (en) * | 2005-03-17 | 2006-12-07 | Amgen Inc. | Methods of decreasing calcification |
| WO2008067199A2 (en) | 2006-11-16 | 2008-06-05 | Kai Pharmaceuticals, Inc. | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders |
| US20080261926A1 (en) * | 2007-04-02 | 2008-10-23 | Liu Julie F | Pharmaceutical Calcimimetics |
| SMT201700014T1 (it) * | 2009-07-29 | 2017-03-08 | Kai Pharmaceuticals Inc | Agenti terapeutici per la riduzione dei livelli dell'ormone paratiroideo |
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
-
2012
- 2012-11-12 AU AU2012335009A patent/AU2012335009B2/en active Active
- 2012-11-12 CA CA2854911A patent/CA2854911C/en active Active
- 2012-11-12 CN CN201910103503.4A patent/CN109985228A/zh active Pending
- 2012-11-12 EP EP12791926.4A patent/EP2776129B2/en active Active
- 2012-11-12 WO PCT/US2012/064717 patent/WO2013071262A1/en not_active Ceased
- 2012-11-12 MX MX2014005662A patent/MX355063B/es active IP Right Grant
- 2012-11-12 JP JP2014541386A patent/JP6204369B2/ja active Active
- 2012-11-12 CN CN201280066707.1A patent/CN104168955A/zh active Pending
- 2012-11-12 US US14/357,702 patent/US20140315809A1/en not_active Abandoned
- 2012-11-12 HK HK15102648.5A patent/HK1202086A1/xx unknown
-
2016
- 2016-03-01 US US15/057,742 patent/US20160175383A1/en not_active Abandoned
-
2017
- 2017-05-23 US US15/603,279 patent/US20170252397A1/en not_active Abandoned
- 2017-06-23 JP JP2017123032A patent/JP2017160269A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20170252397A1 (en) | 2017-09-07 |
| AU2012335009A1 (en) | 2014-05-29 |
| EP2776129B2 (en) | 2020-06-17 |
| AU2012335009B2 (en) | 2017-08-31 |
| JP2015502346A (ja) | 2015-01-22 |
| US20140315809A1 (en) | 2014-10-23 |
| CA2854911C (en) | 2019-09-24 |
| WO2013071262A1 (en) | 2013-05-16 |
| CA2854911A1 (en) | 2013-05-16 |
| JP6204369B2 (ja) | 2017-09-27 |
| EP2776129B1 (en) | 2017-03-29 |
| CN109985228A (zh) | 2019-07-09 |
| EP2776129A1 (en) | 2014-09-17 |
| HK1202086A1 (en) | 2015-09-18 |
| MX2014005662A (es) | 2014-11-10 |
| US20160175383A1 (en) | 2016-06-23 |
| CN104168955A (zh) | 2014-11-26 |
| JP2017160269A (ja) | 2017-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355063B (es) | Calcimiméticos y métodos para su uso. | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX394909B (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos | |
| MX2018006477A (es) | Anticuerpos y metodos de uso de estos. | |
| MX2016012965A (es) | Metodo para preparar amg 416. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| PH12015502275B1 (en) | Therapuetic uses of empagliflozin | |
| BR112015006019A2 (pt) | composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção. | |
| EA201270803A1 (ru) | Тиоацетатные соединения, композиции на их основе и способы их применения | |
| MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
| CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
| EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| MX2014008189A (es) | Composiciones y metodos para tratar trastornos metabolicos. | |
| EA201792465A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| WO2014015157A3 (en) | Sigma receptor ligands for modulating cellular protein homeostasis | |
| MX378726B (es) | Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares. | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| IN2014CN04014A (enExample) | ||
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |